NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
Updated: Feb 10
NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).
RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.
Sponsor
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT03374085
Official Title: A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
First Posted : December 15, 2017
Click here for details on ClinicalTrials.gov
NCI Drug Dictionary info on cereblon E3 ubiquitin ligase modulating agent CC-92480
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2020 ASCO Annual Meeting
Abstract 8500
* cereblon E3 ubiquitin ligase modulating agent CC-92480
* CELMoD CC-92480
* Drug: CC-92480
* Drug: Dexamethasone (Decadron)
- California: City of Hope Duarte
- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver
- Georgia: Emory University Atlanta
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- New York: Roswell Park Cancer Institute Buffalo
- New York: Memorial Sloan-Kettering Cancer Center New York
- Tennessee: Sarah Cannon Research Institute Nashville
- Texas: The University of Texas MD Anderson Cancer Center Houston
Locations
United States, California
United States, Colorado
United States, Georgia
United States, Massachusetts
United States, New York
United States, South Carolina
United States, Tennessee
United States, Texas
United States, Virginia
United States, Washington
Canada
Canada, Alberta
Canada, Ontario
Canada, Quebec
Australia, New South Wales
Australia, South Australia
Australia, Victoria
Europe
United Kingdom
Denmark
Spain
Finland
Belgium
Asia
Japan
Korea, Republic of
RELATED POSTS
NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM
NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
